查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654664

全球膽固醇檢測產品市場 - 2025 至 2033 年

Global Cholesterol Testing Products Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球膽固醇檢測產品市場規模達到 198.5 億美元，預計到 2033 年將達到 422.5 億美元，2025-2033 年預測期間的複合年成長率為 8.8%。

膽固醇測試是測量血液中膽固醇水平的重要診斷程序，有助於評估心臟病、中風和動脈粥狀硬化等心血管疾病的風險。膽固醇檢測產品是測量血液中膽固醇水平的重要工具，在檢測、預防和管理心血管疾病方面發揮著至關重要的作用。

這些產品形式多樣，從傳統的實驗室試劑盒到更方便的即時診斷設備和家庭檢測試劑盒，讓個人和醫療保健提供者都可以輕鬆監測膽固醇水平。透過測量 LDL（壞膽固醇）和 HDL（好膽固醇）等關鍵成分，這些產品有助於評估心臟病的風險並指導治療計劃以改善心臟健康。隨著人們對心臟健康認知的不斷增強，這些膽固醇測試產品的需求也在增加，以支持主動和預防性護理。

市場動態：

促進因素與約束因素

心血管疾病發生率上升

受心血管疾病（CVD）影響的人數不斷增加是推動膽固醇檢測需求的關鍵因素。心臟病和中風已成為全球主要的死亡原因，人們越來越意識到控制膽固醇水平對於維持心臟健康的重要性。高膽固醇是導致這些疾病的主要原因，因此定期進行膽固醇檢測對於醫療保健專業人員和想要預防嚴重健康問題的個人來說都是重要的一步。

隨著越來越多的人被診斷出患有高血壓、肥胖症和糖尿病等相關疾病，對可靠且易於使用的膽固醇檢測工具的需求也越來越大。人們對早期檢測的認知和關注度不斷提高，預計將推動膽固醇檢測市場的發展，更多的人將積極尋求監測和管理膽固醇的方法，以降低心血管疾病的風險。

治療費用高昂

先進膽固醇檢測設備的高成本可能會嚴重阻礙膽固醇檢測產品市場的成長，尤其是在低收入地區或較小的醫療保健提供者。許多先進的膽固醇檢測設備，例如專業實驗室使用的設備或專門的臨床檢測設備，需要大量的前期投資。這些設備通常具有高昂的維護成本、正確使用的訓練要求以及定期校準以確保準確性的需要。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 研發進度
    • 限制
      • 治療費用高昂
    • 機會
    • 影響分析

第5章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 專利分析
  • 監管分析
  • SWOT 分析
  • 未滿足的需求

第 6 章：按產品

  • 裝置
  • 測試套件
  • 其他

第 7 章：按測試類型

  • 總膽固醇測試
  • 低密度脂蛋白（LDL）膽固醇測試
  • 高密度脂蛋白（HDL）膽固醇測試
  • 三酸甘油酯測試
  • 其他

第 8 章：按應用

  • 心血管疾病
  • 糖尿病
  • 肥胖
  • 高血脂症
  • 其他

第 9 章：按最終用戶

  • 醫院
  • 診斷中心
  • 家庭醫療保健
  • 研究實驗室

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Abbott Laboratories
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • F. Hoffmann-La Roche AG
  • Siemens Healthineers GmbH
  • ACON Laboratories Inc.
  • Lepu Medical Technology (Beijing)Co., Ltd.
  • SD Biosensor, INC.
  • Recombigen Laboratories Pvt. Ltd
  • Assure Tech (Hangzhou) Co., Ltd.
  • VP Healthcare
  • SG Diagnostics
  • Similar data will be provided for each market player.
  • Processa 製藥公司
    • 管道產品描述
    • 產品關鍵績效指標 (KPI)
    • 主要活動
    • 市場進入時間表
    • 產品滲透率
    • 銷售估計和預測
  • Vanda 製藥公司
  • Renexxion 愛爾蘭有限公司
  • Aclipse治療公司
  • 將為每個市場參與者提供類似的資料。

第 13 章：附錄

簡介目錄
Product Code: MD4219

The global cholesterol testing products market reached US$ 19.85 billion in 2024 and is expected to reach US$ 42.25 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

Cholesterol testing is a vital diagnostic procedure used to measure the levels of cholesterol in the blood, helping to assess the risk of cardiovascular diseases such as heart disease, stroke, and atherosclerosis. Cholesterol testing products are important tools used to measure cholesterol levels in the blood, playing a vital role in detecting, preventing, and managing cardiovascular diseases.

These products come in various forms, from traditional lab-based kits to more convenient point-of-care devices and at-home testing kits, giving both individuals and healthcare providers easy access to monitor cholesterol levels. By measuring key components like LDL (bad cholesterol) and HDL (good cholesterol), these products help evaluate the risk of heart disease and guide treatment plans to improve heart health. With the growing awareness of heart health, the demand for these cholesterol testing products is increasing, supporting proactive and preventive care.

Market Dynamics: Drivers & Restraints

Rising Incidence of Cardiovascular Diseases

The growing number of people affected by cardiovascular diseases (CVDs) is a key factor driving the demand for cholesterol testing. With heart disease and strokes being the leading causes of death around the world, there's a rising awareness about how crucial it is to keep cholesterol levels in check to maintain heart health. High cholesterol is a major contributor to these conditions, making regular cholesterol testing an important step for both healthcare professionals and individuals who want to prevent serious health issues.

As more people are diagnosed with related conditions like high blood pressure, obesity, and diabetes there's a greater need for reliable and easy-to-use cholesterol testing tools. This growing awareness and focus on early detection are expected to boost the cholesterol testing market, with more people actively seeking ways to monitor and manage their cholesterol to lower the risk of cardiovascular problems.

High Costs of Treatment

The high cost of advanced cholesterol testing devices can significantly hinder the growth of the cholesterol testing products market, especially in low-income regions or for smaller healthcare providers. Many advanced cholesterol testing devices, such as those used in professional labs or specialized point-of-care testing equipment, require significant upfront investment. These devices often come with high maintenance costs, training requirements for proper usage, and the need for regular calibration to ensure accuracy.

Segment Analysis

The global cholesterol testing products market is segmented based on procedure type, device type, surgery type, indication, end-user, and region.

Treatment:

Devices segment is expected to dominate the global cholesterol testing products market share

The devices segment is expected to dominate the cholesterol testing products market due to a combination of technological advancements, growing consumer demand for at-home testing, and the increasing focus on preventive healthcare. With innovations in point-of-care testing devices and self-monitoring kits, cholesterol testing has become more accurate, accessible, and convenient, allowing individuals to monitor their cholesterol levels from the comfort of their homes.

The integration of these devices with mobile apps and digital health platforms further enhances their appeal by enabling real-time tracking and personalized health insights. As the shift toward proactive health management continues, cholesterol testing devices are becoming essential tools for both healthcare professionals and consumers, driving widespread adoption and market growth. Their ability to provide quick, reliable results at an affordable cost positions them as the leading solution in the market.

Geographical Analysis

North America is expected to hold a significant position in the global cholesterol testing products market share

North America is leading the cholesterol testing products market due to high levels of awareness about heart health, and a strong emphasis on preventive care. The region benefits from well-established healthcare systems, widespread access to cutting-edge medical devices, and a growing focus on early detection and management of cardiovascular diseases. In addition, both the U.S. and Canada have robust health insurance systems that often cover the cost of cholesterol testing, making it more accessible to the general population.

The increasing prevalence of high cholesterol, coupled with rising healthcare awareness campaigns, has driven the adoption of cholesterol testing products, further solidifying North America's dominance in the market. For instance, according to the Tebra Inc. in 2024, approximately 71 million Americans have high cholesterol, and although there are many potential causes, one key factor is that certain habits can raise cholesterol levels without people even realizing it. Furthermore, the integration of innovative technologies like point-of-care testing devices and digital health solutions has contributed to the region's leadership in cholesterol monitoring.

Competitive Landscape

The major global players in the cholesterol testing products market include Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers GmbH, ACON Laboratories Inc., Lepu Medical Technology (Beijing)Co., Ltd., SD Biosensor, INC., Recombigen Laboratories Pvt. Ltd, Assure Tech (Hangzhou) Co., Ltd., V.P. Healthcare and SG Diagnostics among others.

Key Developments

  • In August 2024, AstraZeneca's Imfinzi (durvalumab) received approval in the United States for use in combination with chemotherapy to treat adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.
  • In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test. This approval provides a new personalized treatment option for patients with this specific mutation in their cancer.
  • In August 2023, Eli Lilly and Company announced the topline results from the LIBRETTO-431 study, which evaluated Retevmo (selpercatinib) against platinum-based chemotherapy plus pemetrexed as an initial treatment for patients with rearranged during transfection (RET) fusion-positive advanced or metastatic non-small cell lung cancer (NSCLC).

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Cholesterol Testing Products Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Test Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancements in Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
    • 6.1.2. Market Attractiveness Index, By Product
  • 6.2. Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Test Kits
  • 6.4. Others

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type
  • 7.2. Total Cholesterol Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Low Density-Lipoprotein (LDL) Cholesterol Tests
  • 7.4. High-Density Lipoprotein (HDL) Cholesterol Tests
  • 7.5. Triglycerides Tests
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiovascular Diseases*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diabetes
  • 8.4. Obesity
  • 8.5. Hyperlipidemia
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Home Healthcare
  • 9.5. Research Laboratories

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. F. Hoffmann-La Roche AG
  • 12.3. Siemens Healthineers GmbH
  • 12.4. ACON Laboratories Inc.
  • 12.5. Lepu Medical Technology (Beijing)Co., Ltd.
  • 12.6. SD Biosensor, INC.
  • 12.7. Recombigen Laboratories Pvt. Ltd
  • 12.8. Assure Tech (Hangzhou) Co., Ltd.
  • 12.9. V.P. Healthcare
  • 12.10. SG Diagnostics
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Processa Pharmaceuticals, Inc.*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Vanda Pharmaceuticals Inc.
  • 12.13. Renexxion Ireland Limited
  • 12.14. Aclipse Therapeutics
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us